Autophagy modulation: A target for cancer treatment development

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 3, 2015, Pages 439-447

  Duffy, Alison ^a   Le, Jackson ^b   Sausville, Edward ^c   Emadi, Ashkan ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b GEISINGER HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Autophagy; Cell death; Hydroxychloroquine

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BAFILOMYCIN; BORTEZOMIB; CHLOROQUINE; EVEROLIMUS; HYDROXYCHLOROQUINE; TEMSIROLIMUS; VORINOSTAT;

ADVANCED CANCER; APOPTOSIS; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESISTANCE; CELL DEATH; CELL STRUCTURE; CELLS BY BODY ANATOMY; CLINICAL TRIAL (TOPIC); HUMAN; KIDNEY CANCER; LEUKEMIA; MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84925534889     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2637-z     Document Type: Review

References (30)

1. Mizushima N, Komatsu M (2011) Autophagy: renovation of cells and tissues. Cell 147:728-741. doi: 10.1016/j.cell.2011.10.026
2. Klionsky DJ (2005) The molecular machinery of autophagy: unanswered questions. J Cell Sci 118:7-18. doi: 10.1242/jcs.01620
3. Yang ZJ, Chee CE, Huang S, Sinicrope FA (2011) The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10:1533-1541. doi: 10.1158/1535-7163.MCT-11-0047
4. Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P (2008) Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 90:313-323. doi: 10.1016/j.biochi.2007.08.014
5. Amaravadi RK, Lippincott-Schwartz J, Yin X-M et al (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:654-666. doi: 10.1158/1078-0432.CCR-10-2634
6. Xie X, White EP, Mehnert JM (2013) Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS ONE 8:e55096. doi: 10.1371/journal.pone.0055096
7. Jung CH, Jun CB, Ro S-H et al (2009) ULK-Atg13-FIP200 complexes mediate mtor signaling to the autophagy machinery. Mol Biol Cell 20:1992-2003. doi: 10.1091/mbc.E08-12-1249
8. Chaabane W, User SD, El-Gazzah M et al (2012) Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp 61:43-58. doi: 10.1007/s00005-012-0205-y
9. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497-5510. doi: 10.1038/onc.2008.245
10. Rubinsztein DC, Codogno P, Levine B (2012) Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 11:709-730. doi: 10.1038/nrd3802
11. Vignot S (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537. doi: 10.1093/annonc/mdi113
12. Rosich L, Xargay-Torrent S, López-Guerra M et al (2012) Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res 18:5278-5289. doi: 10.1158/1078-0432.CCR-12-0351
13. MacCallum SF, Groves MJ, James J et al (2013) Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep 3:1275. doi: 10.1038/srep01275
14. Trisciuoglio D, De Luca T, Desideri M et al (2013) Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth. Neoplasia 15:315-327
15. Zhu K, Dunner K, McConkey DJ (2009) Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29:451-462. doi: 10.1038/onc.2009.343
16. Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101:18030-18035. doi: 10.1073/pnas.0408345102
17. Ertmer A, Huber V, Gilch S et al (2007) The anticancer drug imatinib induces cellular autophagy. Leukemia 21:936-942. doi: 10.1038/sj.leu.2404606
18. Yogalingam G, Pendergast AM (2008) Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components. J Biol Chem 283:35941-35953. doi: 10.1074/jbc.M804543200
19. Funakoshi T, Latif A, Galsky MD (2014) Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev. doi: 10.1016/j.ctrv.2014.02.004
20. Yang ZJ, Chee CE, Huang S, Sinicrope F (2011) Autophagy modulation for cancer therapy. Cancer Biol Ther 11:169-176. doi: 10.4161/cbt.11.2.14663
21. Kaufmann AM, Krise JP (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96:729-746. doi: 10.1002/jps.20792
22. Sotelo J, Briceño E, López-González MA (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:337-343
23. Rosenfeld MR, Ye X, Supko JG et al (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359-1368. doi: 10.4161/auto.28984
24. Mahalingam D, Mita M, Sarantopoulos J et al (2014) Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10:1403-1414. doi: 10.4161/auto.29231
25. Vogl DT, Stadtmauer EA, Tan K-S et al (2014) Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10:1380-1390. doi: 10.4161/auto.29264
26. Rangwala R, Chang YC, Hu J et al (2014) Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10:1391-1402. doi: 10.4161/auto.29119
27. Barnard RA, Wittenburg LA, Amaravadi RK et al (2014) Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 10:1415-1425. doi: 10.4161/auto.29165
28. Rangwala R, Leone R, Chang YC et al (2014) Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10:1369-1379. doi: 10.4161/auto.29118
29. Zhou C, Wu Y-L, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742. doi: 10.1016/S1470-2045(11)70184-X
30. Goldberg SB, Supko JG, Neal JW et al (2012) A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 7:1602-1608. doi: 10.1097/JTO.0b013e318262de4a